Singapore markets closed
Straits Times Index
3,296.89 +4.20 (+0.13%) S&P 500
5,022.68 +4.29 (+0.09%) Dow
37,958.50 +55.21 (+0.15%) Nasdaq
15,651.84 +46.36 (+0.30%) Bitcoin USD
58,422.07 +1,188.11 (+2.08%) CMC Crypto 200
1,263.12 -7.63 (-0.60%)
NovoCure Limited (NVCR)
NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
As of 10:02AM EDT. Market open.
| Previous close | 12.74 |
| Open | 13.39 |
| Bid | 11.33 x 200 |
| Ask | 13.20 x 200 |
| Day's range | 12.17 - 13.45 |
| 52-week range | 10.87 - 83.60 |
| Volume | |
| Avg. volume | 1,289,957 |
| Market cap | 1.317B |
| Beta (5Y monthly) | 0.43 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- GuruFocus.com
NovoCure Ltd (NVCR) Q1 2024 Earnings: Revenue Surpasses Estimates, Narrower Net Loss Reported
Comprehensive Analysis of NovoCure's First Quarter Financial Performance
- Zacks
NovoCure (NVCR) Reports Q1 Loss, Tops Revenue Estimates
NovoCure (NVCR) delivered earnings and revenue surprises of 16.28% and 5.30%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
- Zacks
NovoCure (NVCR) Expected to Beat Earnings Estimates: Should You Buy?
NovoCure (NVCR) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
© 2024 Yahoo. All rights reserved.